BACKGROUND: A recent case-control study suggested a benefit of hydroxychloroquine (HCQ) in lowering the risk of cardiac manifestations of neonatal lupus (cardiac-NL) in pregnancies of anti-SSA/Ro-positive patients with systemic lupus erythematosus. A historical cohort assembled from 3 international databases was used to evaluate whether HCQ reduces the nearly 10-fold increase in risk of recurrence of cardiac-NL independently of maternal health status. METHODS AND RESULTS: Two hundred fifty-seven pregnancies of anti-SSA/Ro-positive mothers (40 exposed and 217 unexposed to HCQ) subsequent to the birth of a child with cardiac-NL were identified from 3 databases (United States, England, and France). Exposure was defined as the sustained use of HCQ throughout pregnancy with initiation before 10 weeks of gestation. The recurrence rate of cardiac-NL in fetuses exposed to HCQ was 7.5% (3 of 40) compared with 21.2% (46 of 217) in the unexposed group (P=0.050). Although there were no deaths in the exposed group, the overall case fatality rate of the cardiac-NL fetuses in the unexposed group was 21.7%. In a multivariable analysis that adjusted for database source, maternal race/ethnicity, and anti-SSB/La status, HCQ use remained significantly associated with a decreased risk of cardiac-NL (odds ratio, 0.23; 95% confidence interval, 0.06-0.92; P=0.037). Similar results were obtained with propensity score analysis, an alternative approach to adjust for possible confounding by indication. CONCLUSION: Aggregate data from a multinational effort show that in mothers at high risk of having a child with cardiac-NL, the use of HCQ may protect against recurrence of disease in a subsequent pregnancy.
BACKGROUND: A recent case-control study suggested a benefit of hydroxychloroquine (HCQ) in lowering the risk of cardiac manifestations of neonatal lupus (cardiac-NL) in pregnancies of anti-SSA/Ro-positive patients with systemic lupus erythematosus. A historical cohort assembled from 3 international databases was used to evaluate whether HCQ reduces the nearly 10-fold increase in risk of recurrence of cardiac-NL independently of maternal health status. METHODS AND RESULTS: Two hundred fifty-seven pregnancies of anti-SSA/Ro-positive mothers (40 exposed and 217 unexposed to HCQ) subsequent to the birth of a child with cardiac-NL were identified from 3 databases (United States, England, and France). Exposure was defined as the sustained use of HCQ throughout pregnancy with initiation before 10 weeks of gestation. The recurrence rate of cardiac-NL in fetuses exposed to HCQ was 7.5% (3 of 40) compared with 21.2% (46 of 217) in the unexposed group (P=0.050). Although there were no deaths in the exposed group, the overall case fatality rate of the cardiac-NL fetuses in the unexposed group was 21.7%. In a multivariable analysis that adjusted for database source, maternal race/ethnicity, and anti-SSB/La status, HCQ use remained significantly associated with a decreased risk of cardiac-NL (odds ratio, 0.23; 95% confidence interval, 0.06-0.92; P=0.037). Similar results were obtained with propensity score analysis, an alternative approach to adjust for possible confounding by indication. CONCLUSION: Aggregate data from a multinational effort show that in mothers at high risk of having a child with cardiac-NL, the use of HCQ may protect against recurrence of disease in a subsequent pregnancy.
Authors: Aurélie Ambrosi; Stina Salomonsson; Håkan Eliasson; Elisabeth Zeffer; Amanda Skog; Vijole Dzikaite; Gunnar Bergman; Eva Fernlund; Joanna Tingström; Elke Theander; Annika Rydberg; Thomas Skogh; Annika Öhman; Ulla Lundström; Mats Mellander; Ola Winqvist; Michael Fored; Anders Ekbom; Lars Alfredsson; Henrik Källberg; Tomas Olsson; Fredrik Gadler; Anders Jonzon; Ingrid Kockum; Sven-Erik Sonesson; Marie Wahren-Herlenius Journal: Ann Rheum Dis Date: 2011-09-27 Impact factor: 19.103
Authors: A Brucato; M Frassi; F Franceschini; R Cimaz; D Faden; M P Pisoni; M Muscarà; G Vignati; M Stramba-Badiale; L Catelli; A Lojacono; I Cavazzana; A Ghirardello; F Vescovi; P F Gambari; A Doria; P L Meroni; A Tincani Journal: Arthritis Rheum Date: 2001-08
Authors: Gordon Gladman; Earl D Silverman; Lily Luy; Christine Boutin; Carl Laskin; Jeffrey F Smallhorn Journal: Am J Perinatol Date: 2002-02 Impact factor: 1.862
Authors: N Costedoat-Chalumeau; Z Amoura; D Le Thi Hong; B Wechsler; D Vauthier; P Ghillani; T Papo; O Fain; L Musset; J-C Piette Journal: Ann Rheum Dis Date: 2003-10 Impact factor: 19.103
Authors: Megan E B Clowse; Amanda M Eudy; Elizabeth Kiernan; Matthew R Williams; Bonnie Bermas; Eliza Chakravarty; Lisa R Sammaritano; Christina D Chambers; Jill Buyon Journal: Rheumatology (Oxford) Date: 2018-07-01 Impact factor: 7.580
Authors: Robert M Clancy; Androo J Markham; Joanne H Reed; Miroslav Blumenberg; Marc K Halushka; Jill P Buyon Journal: J Autoimmun Date: 2015-10-01 Impact factor: 7.094
Authors: Joanne H Reed; Manish Jain; Kristen Lee; Ekambar R Kandimalla; Mohd Hafeez Faridi; Jill P Buyon; Vineet Gupta; Robert M Clancy Journal: J Biol Chem Date: 2013-02-05 Impact factor: 5.157
Authors: Federica Vanoni; Sebastiano A G Lava; Emilio F Fossali; Riccardo Cavalli; Giacomo D Simonetti; Mario G Bianchetti; Marie-Ange Bozzini; Carlo Agostoni; Gregorio P Milani Journal: Clin Rev Allergy Immunol Date: 2017-12 Impact factor: 8.667